Summary of WuXi AppTec Conference Call Company Overview - **Company**: WuXi AppTec - **Industry**: Contract Research, Development, and Manufacturing Organization (CRDMO) Key Financial Guidance - **2026 Revenue Guidance**: Expected to be between 51.3 billion and 53 billion RMB, with a constant currency growth rate of 22%-26% [2][3] - **Backlog Orders**: As of the end of 2025, backlog orders reached 58 billion RMB, representing a year-on-year increase of 28.8%, and a 34% increase when excluding currency effects [2][3] - **Order Conversion Rate**: Anticipated to be around 70% over the next 12 months, indicating improved business visibility [2][12] Business Segments Performance - **TIDES Business (Peptides/Nucleic Acids)**: Expected to exceed 10 billion RMB in revenue by 2025, with a projected growth of 30%-40% in 2026 when excluding currency effects [2][5] - **Small Molecule CDMO**: Expected to recover to double-digit growth in 2025, with acceleration anticipated in 2026 [2][11] - **Testing and Biology Segments**: Both segments achieved double-digit growth, reflecting a recovery in early-stage research financing [2][11] Capital Expenditure - **2026 Capital Expenditure Guidance**: Expected to be between 6.5 billion and 7.5 billion RMB, primarily focused on expanding global capacity for small molecules and new molecules [2][15] Profitability Insights - **Adjusted Net Profit Margin**: Reached approximately 35% in Q4 2025, with expectations to remain stable and resilient in 2026 [2][5] - **Inventory Levels**: Increased to 9 billion RMB, driven by the need to support later-stage and commercial projects [2][9] Market Dynamics - **Raw Material Costs**: Rising oil prices may impact chemical raw material costs, which account for 40%-50% of CDMO operating costs [4] - **Global R&D Financing**: Observed recovery in early-stage R&D financing, with positive trends in order volume and customer inquiries [6][11] Regulatory and Governance - **1,260H List Concerns**: Company emphasizes transparency and governance, asserting no government or military affiliations, and plans to address any misunderstandings [2][13][14] Competitive Landscape - **Foreign Investment in China**: Notable investments from multinational corporations (MNCs) in China, indicating a trend towards localized supply chains [10][18] Future Outlook - **2026 Revenue Growth**: Expected growth of 18%-22%, with a focus on maintaining a stable order-to-revenue conversion rate [3][12] - **AI Integration**: Company is leveraging AI to enhance operational efficiency and industry insights, which is expected to positively impact profitability [20] Conclusion - WuXi AppTec is positioned for robust growth in 2026, driven by strong order backlogs, strategic capital investments, and a focus on high-margin business segments. The company is navigating market challenges while maintaining a commitment to transparency and operational excellence.

Core Insights - The Chinese pharmaceutical industry is transitioning from "generic" to "innovative" drugs, entering a phase of explosive growth after years of technological accumulation and industry maturation [1][3] - In the first half of this year, China approved 43 innovative drugs, a 59% increase year-on-year, marking a historical high for the same period [1] - Business development (BD) activities have exceeded 50 cases with a total value surpassing $48 billion, indicating strong market interest in domestic innovations [1] Industry Trends - The Chinese innovative drug sector has moved from initial exploration to a mature growth phase, significantly reducing the time gap for drug approval compared to the U.S. from 10 years in 2010 to 3.7 years in 2024 [3] - The industry faces challenges of high homogeneity in drug development, with 29% of all drug applications targeting the top 20 drug development targets [3][4] - Companies are focusing on creating differentiated advantages by targeting unmet clinical needs or developing new products in less explored areas [4] Policy and Capital Support - The Chinese government has introduced a comprehensive support system for innovative drugs, including 16 measures covering research, insurance access, and clinical use [5][6] - Recent regulatory changes have facilitated capital access for innovative drug companies, allowing them to secure funding for research and development [5][6] Globalization and Market Expansion - Chinese pharmaceutical companies are increasingly becoming key contributors to global innovation, with nearly half of the global BD transactions exceeding $50 million involving Chinese firms [2][7] - The trend of "license out" and strategic partnerships is becoming more prevalent as companies seek to expand their international presence [8][9] - The cost advantages in clinical trials in China, where the cost per participant is about one-third of that in the U.S., are enhancing the competitiveness of Chinese biotech firms [9] Technological Innovation - The application of AI technologies is revolutionizing the Chinese innovative drug sector, improving efficiency in drug development and clinical research [9] - Companies are integrating AI into their processes to enhance research efficiency and data value, which is crucial for global competitiveness [9]